NCT00956449View on ClinicalTrials.gov

Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

July 31, 2009

Study Completion Date

July 31, 2009

Conditions
InfluenzaSeasonal Influenza
Interventions
BIOLOGICAL

Seasonal Influenza Vaccine

1 dose of Influenza Vaccine Surface Antigen, Inactivated

Trial Locations (1)

IP309QU

The Health Centre, Suffolk

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Novartis Vaccines
All Listed Sponsors
collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY